Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 6/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109880 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL121327 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL109881 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL11679276 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL114111 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL111416 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL114110 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL112094 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL11679280 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 | |
| SCHEMBL112093 | 1.00 | PLA2G2C (0.47) | PLA2G2CNOD1EPHX1TSHRTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | claimed |
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| CN-102655858-B | ABT-263 capsule | ABBVIE (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-102802605-B | Stable lipid formulations of apoptosis promoters | ABBVIE (US) | 2015-08-12 | — | — | CN | disclosed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8362013-B2 | Salt of ABT-263 and solid-state forms thereof | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362014-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102802605-A | Stable lipid formulations of apoptosis promoters | ABBOTT LAB | 2012-11-28 | — | — | CN | disclosed |
| US-20110071151-A1 | ABT-263 CRYSTALLINE FORMS | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2010147899-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBVIE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES | 2010-11-25 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | BCL2L10, TMBIM6, BCOR | PLA2G2C 1555/4885NOD1 1503/4885EPHX1 4611/4885 |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCL2L2 | PLA2G2C 2060/4885NOD1 2124/4885EPHX1 4586/4885 |
| US-20110071151-A1 | ABT-263 CRYSTALLINE FORMS | BCL3, BCL2, BCL2L13 | PLA2G2C 3243/4885NOD1 631/4885EPHX1 4857/4885 |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | BCL3, BCL2, BCL2L13 | PLA2G2C 1899/4885NOD1 2221/4885EPHX1 4845/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | PLA2G2C 631/4885NOD1 2795/4885EPHX1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.